ENTO

0.509

16.48% 0.072

Handel nachbörslich: .48 -0.029 -5.70%

Entero Therapeutics Inc (ENTO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$0.437

Offen:

$0.53

24-Stunden-Volumen:

17.74M

Relative Volume:

30.86

Marktkapitalisierung:

$1.88M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

+5.95%

1M Leistung:

+0.02%

6M Leistung:

-15.12%

1J Leistung:

+0.00%

1-Tages-Spanne:

$0.3711

$0.55

1-Wochen-Bereich:

$0.37

$0.55

52-Wochen-Spanne:

$0.185

$3.00

Entero Therapeutics Inc Stock (ENTO) Company Profile

Firmenname

Entero Therapeutics Inc

Sektor

Healthcare (1172)

Branche

Biotechnology (673)

Telefon

561-589-7020

Adresse

777 YAMATO ROAD, BOCA RATON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

ENTO's Discussions on Twitter

Vergleichen Sie ENTO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ENTO Entero Therapeutics Inc	0.509	1.88M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	474.62	125.40B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	65.79B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	35.18B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	32.67B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	26.46B	3.81B	-644.79M	-669.77M	-6.24

Entero Therapeutics Inc Aktie (ENTO) Neueste Nachrichten

08:05 AM

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

08:05 AM

05:20 AM

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

05:20 AM

Apr 03, 2025

Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener

Mar 25, 2025

Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN

Mar 25, 2025

Mar 24, 2025

Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan

Mar 24, 2025

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance

Mar 24, 2025

Mar 21, 2025

Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail

Mar 21, 2025

Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail

Mar 21, 2025

Hogs Close with Weakness on Thursday - The Globe and Mail

Mar 21, 2025

Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace

Mar 21, 2025

Mar 20, 2025

With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail

Mar 20, 2025

This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail

Mar 20, 2025

Mar 19, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail

Mar 19, 2025

Mar 18, 2025

European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail

Mar 18, 2025

The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail

Mar 18, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 17, 2025

Celiac Disease Market Expected to Experience Major Growth - openPR

Mar 17, 2025

Significant Contract News Sends Energy Services Company Higher - The Globe and Mail

Mar 17, 2025

How Nvidia (NASDAQ:NVDA) Stayed One Step Ahead in the AI Race - The Globe and Mail

Mar 17, 2025

Super Micro's International Presence Makes It a Winning Stock - The Globe and Mail

Mar 17, 2025

Vicarious Surgical Names Sarah Romano as Finance Chief - MPO-mag

Mar 17, 2025

Mar 15, 2025

3 Artificial Intelligence (AI) Stocks That Can Weather President Trump's Tariff Storm - The Globe and Mail

Mar 15, 2025

Mar 14, 2025

Vicarious Surgical appoints Sarah Romano as CFO - MedTech Dive

Mar 14, 2025

Can Nvidia’s Stock Keep Climbing as Foxconn Bets Big on AI? - The Globe and Mail

Mar 14, 2025

Greif Named 2025 Gallup Exceptional Workplace Award Winner - The Globe and Mail

Mar 14, 2025

Mar 13, 2025

Vicarious Surgical names Sarah Romano as new CFO By Investing.com - Investing.com Australia

Mar 13, 2025

Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer - citybiz

Mar 13, 2025

Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer - Business Wire

Mar 13, 2025

Vicarious Surgical names Sarah Romano as new CFO - Investing.com

Mar 13, 2025

Mar 12, 2025

3 Ways Tech Investors Can Navigate the Artificial Intelligence (AI) Sector Tumble - The Globe and Mail

Mar 12, 2025

Mar 11, 2025

Stocks Mixed as President Trump Ramps Up Tariffs on Canada - The Globe and Mail

Mar 11, 2025

Mar 10, 2025

Goldman Sachs: Buy These 2 ‘Rising Star’ Stocks in 2025 - The Globe and Mail

Mar 10, 2025

Mar 05, 2025

Where Will Coca-Cola Stock Be in 5 Years? - The Globe and Mail

Mar 05, 2025

Mar 04, 2025

Reflecting On Auto Parts Retailer Stocks’ Q4 Earnings: AutoZone (NYSE:AZO) - The Globe and Mail

Mar 04, 2025

Mar 03, 2025

Onconetix taps industry veteran as executive chairman amid CEO resignationCincinnati Business Courier - Cincinnati Business Courier

Mar 03, 2025

Feb 28, 2025

Onconetix names new executive chairman, appoints board member - Investing.com

Feb 28, 2025

Feb 26, 2025

iHeartMedia (IHRT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail

Feb 26, 2025

Feb 17, 2025

Entero Therapeutics Appoints Richard Paolone as CEO - citybiz

Feb 17, 2025

Feb 16, 2025

AzurRx BioPharma Receives Approximately $550,000 for its 2020 CIR (French Research Tax Credit) - Marketscreener.com

Feb 16, 2025

Feb 15, 2025

Entero Therapeutics names Richard Paolone interim CEO - MSN

Feb 15, 2025

Feb 14, 2025

Entero Therapeutics Appoints Richard Paolone as Interim CEO - TipRanks

Feb 14, 2025

Entero Therapeutics names Richard Paolone interim CEO By Investing.com - Investing.com South Africa

Feb 14, 2025

Entero Therapeutics Names Richard Paolone Interim CEO - MarketWatch

Feb 14, 2025

Entero Therapeutics Names Richard Paolone Interim CEO -February 14, 2025 at 04:25 pm EST - Marketscreener.com

Feb 14, 2025

Strategic Leadership Shift: M&A Expert Takes Helm at Entero TherapeuticsKey Details Revealed - StockTitan

Feb 14, 2025

Feb 11, 2025

Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - Marketscreener.com

Feb 11, 2025

Feb 10, 2025